[Cell-mediated immunity using anti-influenza vaccine (AIV) and an immunostimulant (R)]

21 infected asthmatics were involved in this study, divided into three groups: Group 1 (G1): 7 subjects who received Ribomunyl. Group 2 (G2): 7 subjects who received anti-influenza vaccine, replaced on the 8th day by Ribomunyl. Group 3 (G3): 7 subjects who received the anti-influenza vaccine. Every patient had a IMC assessment on days 0, 8 and 30 that was composed of: 1. An RE test to show the Ly T11 receptors. 2. A study of the lymphocyte sub-populations CD3, CD4 and CD8, that respectively exhibit the LyT, T-helper and T-suppressor receptors. 3. Lymphocyte function was studied by stimulation of the lymphocytes by lectins, PHA (Ly T), Con A (Ly Ts) PKWM (Ly 8): by TB co-operation). 4. Measurement of total IgE. Only the lymphocyte stimulation tests by lectins showed a significantly raised response in the subjects of G1, who received Ribomunyl. IAV and Ribomunyl (G2) or IAV alone (G3) showed lymphocytes responses that were statistically less than G1. It seemed as though the IAV retarded the Ribomunyl response in IMC. The RE test and the study of the sub-populations did not show any significant differences between the groups. No differences between the total IgE levels could be seen in the groups. This study indicates the possibilities in the treatment of super-infected asthmatics with Ribomunyl alone, since the anti-influenza vaccine had a tendency to retard cell-mediated immunity.